Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.
Patients are enrolled following completion or early discontinuation from a Novartis sponsored or supported study of CAR T-Cell treatment. Patients will be followed for 15 years post treatment from the last treatment. They will be monitored for safety and efficacy within the primary treatment protocols for the protocol defined duration. Patients can drop off treatment protocols at any time to enter this long term Follow up study. Patients discontinuing from the primary treatment protocols for any reason will be enrolled in this long term follow up (LTFU). This will allow collecting data on long term safety and efficacy (as applicable) as mandated by the health authorities of all patients treated with CAR-T therapy within the concept of a single protocol.
Collection of such long term effects of CAR-T cell therapy will help to further define the risk-benefit profile of CAR-T Therapies.
Inclusion Criteria:
Exclusion Criteria:
1-888-669-6682
+41613241111
Duarte, California 91010 3000, United States
Atlanta, Georgia 30322, United States
Atlanta, Georgia 30322, United States
Chicago, Illinois 60637, United States
Durham, North Carolina 27705, United States
Chuo Ku, Tokyo 104 0045, Japan
Esplugues, Barcelona 08950, Spain
lchen@chla.usc.edu323-361-5812
310-825-4493
jenai.wilmoth@ucsf.edu415-514-6281
Baggott@stanford.edu650-723-4000
Sharra.triplett@emory.edu
keshawna.sherer@emoryhealthcare.org404-778-3708
audrey.tumlin@choa.org+1 404 785 2125
lschroed@medicine.bsd.uchicago.edu773-834-0982
hweiner@medicine.bsd.uchicago.edu773-834-0982
nsmart@kumc.edu913-588-6029
mfarris@kumc.edu913-588-6029
617-667-7000
617-632-3985
sgomes@med.umich.edu
sgomes@med.umich.edu734-936-8538
smimiche@umich.edu734-936-8538
313-576-8716
almiles1@cmh.edu816-855-1886
rwilcox@cmh.edu816-302-6851
kristine.gurganus@dm.duke.edu919-668-2967
erin.arbuckle@duke.edu919-684-3293
nelson.chao@duke.edu
melanie.jordan@cchmc.org513-636-9292
kristie.stricker@chmc.org+1 513 636 9292
Molly.Vittorio@osumc.edu614-688-9494
zentzis@ohsu.edu503-346-1507
yap@ohsu.edu+1 503 494 6865
VERNAUL@EMAIL.CHOP.EDU215-590-7399
mcaylor@mail.med.upenn.edu215-898-9256
dfend@upenn.edu215-615-1725
215-955-8699
Alison.patterson@childrens.com214-456-2726
cris.molina@childrens.com214-648-6449
souzouni@mdanderson.org713-792-2171
lehargraves@mdanderson.org713-792-6594
souzouni@mdanderson.org713-792-2171
luke.stone@hsc.utah.edu801-213-3395
Sydney.Goosen@hsc.utah.edu801-213-3401
PedsHemOncResearch@lists.wisc.edu608-890-8070
camatsus@pediatrics.wisc.edu+1 608-890-8069
kgrindle@uwhealth.org